Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM

Launched by PEKING UNIVERSITY CANCER HOSPITAL & INSTITUTE · Jun 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how well and how safely two treatments work for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. The study compares a combination of two treatments—DEB-TACE (a way to deliver cancer medicine directly to the liver using tiny beads) combined with HAIC (a method that delivers chemotherapy directly into the liver)—to HAIC alone. The goal is to see if adding DEB-TACE to HAIC helps control the cancer better and is safe for patients.

People who might join this study are adults aged 18 or older who have been diagnosed with colorectal cancer that has spread to their liver and have at least one tumor that can be measured on scans. They should be in generally good health (able to carry out daily activities with some limitations) and have liver function within certain limits. Participants must not be receiving other cancer treatments during the study period, and they need to have recent imaging tests available for doctors to track the cancer’s response. The study is not yet recruiting, but if you qualify, you can expect to receive one of these treatment options and have regular check-ups to monitor how well the treatment is working and to watch for any side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years
• • 2. No gender restriction
• • 3. Pathologically or clinically diagnosed with colorectal liver metastases
• • 4. Imaging data available within 31 days prior to enrollment, with at least one measurable lesion (according to RECIST criteria)
• • 5. Patients received only DEB-TACE combined with HAIC or HAIC alone during the observation period
• • 6. Child-Pugh classification A or B
• • 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Exclusion Criteria:
• • 1. Presence of treatment risks or contraindications to DEB-TACE combined with HAIC or HAIC alone.
• • 2. Concurrent diagnosis of other malignancies.
• • 3. Underwent other local treatment modalities during the observation period.
• • 4. DEB-TACE combined with HAIC or HAIC alone was used as postoperative adjuvant therapy.
• • 5. Missing relevant examination results before or after treatment.
• • 6. Incomplete imaging data, making response evaluation impossible.
• • 7. Follow-up failure due to incorrect or missing patient information, loss to follow-up, or patient refusal.
• • -